Background-Rheumatic heart disease is the most common cause of valvular disease in developing countries. Despite the high prevalence of this disease, the cellular mechanisms are not well known. We hypothesized that rheumatic valve calcification is associated with an osteoblast bone formation and neoangiogenesis. Methods and Results-To test this hypothesis, we examined human rheumatic valves replaced at surgery (nϭ23), normal human valves (nϭ20) removed at cardiac transplantation, and degenerative mitral valve leaflets removed during surgical valve repair (nϭ15). Microcomputed tomography was used to assess mineralization fronts to reconstruct the extents of mineralization. Immunohistochemistry was used to localize osteopontin protein, ␣-actin, osteocalcin, vascular endothelial growth factor, von Willebrand factor, and CD68 (human macrophage). Microcomputed tomography demonstrated complex calcification developing within the heavily calcified rheumatic valves, not in the degenerative mitral valves and control valves. Immunohistochemistry localized osteopontin and osteocalcin to areas of smooth muscle cells within microvessels and proliferating myofibroblasts. Vascular endothelial growth factor was present in areas of inflammation and colocalized with the CD68 stain primarily in the calcified rheumatic valves. Alizarin red, osteopontin, and osteocalcin protein expression was upregulated in the calcified rheumatic valves and was present at low levels in the degenerative mitral valves. Conclusions-These findings support the concept that rheumatic valve calcification is not a random passive process but a regulated, inflammatory cellular process associated with the expression of osteoblast markers and neoangiogenesis. (Circulation. 2005;111:3296-3301.)
R heumatic valvular heart disease is the most common cause of valvular heart disease in developing countries. Improvement in living standards and the aggressive treatment of penicillin-sensitive group A ␤-hemolytic Streptococcus are changing the epidemiology of rheumatic valve disease throughout the world. In 1924, Dr Carey Coombs wrote the first systematic textbook on rheumatic heart disease, describing the inflammatory lesion in the rheumatic valve leaflet and the presence of new vessels developing within the valve. 1 Since 1924, a number of studies have demonstrated the histopathology of this disease with correlations of the degree of rheumatic activity, which include the presence of Aschoff bodies, nonspecific edema, and leukocyte infiltration. 2, 3 Despite the high prevalence, increased morbidity, and well-described histopatho-logical findings of this disease, little is known about the cellular mechanisms responsible for calcification in these valves. Recently, our laboratory and others have demonstrated that calcification in nonrheumatic, "degenerative" stenotic aortic valves removed at the time of surgical valve replacement is associated with an osteoblast-like phenotype. 4, 5 We hypothesized that the inflammatory valve lesion in rheumatic valve disease is associated with angiogenesis and osteogenesis, which may contribute to the disease progression in this patient population. To test our hypothesis, we examined human calcified rheumatic valves compared with degenerative mitral valves for the expression of osteoblast, inflammatory, and angiogenesis markers to define the presence of these markers and to compare the levels of the bone formation process in different valve lesions.
Methods

Human Calcified Rheumatic Valves and Degenerative Mitral Valves
The use of all human tissue was approved by the Human Subject Protection Offices at the Mayo Clinic (MC) (1732-98) and Northwestern University (1041-002). Coded tissues were collected at the time of surgery and autopsy. We obtained human calcified mitral and aortic rheumatic valves from patients (MC) (nϭ23; mean age, 72 years; range, 44 to Ͼ89 years; male, 13; female, 10) at the time of surgical valve replacement. We compared them to degenerative mitral valve tissue (MC) (nϭ15; mean age, 72 years; range, 54 to Ͼ89 years; male, 14; female, 1) removed at the time of surgical valve repair. Normal control valves were obtained from the time of heart transplantation (MC) (nϭ20; mean age, 51 years; range, 19 to 56 years; male, 16; female, 4). Upon dissection, tissues were immersed in formalin for paraffin embedding. A total of 6 valves were obtained for microCT analysis from Northwestern University, from which no patient identifiers were obtained.
Immunohistochemistry Analysis
Immunostaining of the valves for demonstration of angiogenesis, cellular proliferation, and bone matrix protein expression was performed on paraffin-embedded tissues using a streptavidin-biotin method. Angiogenic factors, endothelial cells, macrophage cells, proliferating nuclear cell antigen (PCNA), and osteopontin were tested. The following primary antibody was used for angiogenic factor detection: anti-vascular endothelial growth factor (VEGF; Oncogene). Anti-␣-actin (Dako, A/S) was used to detect the presence of myofibroblast cells and smooth muscle cells, and anti-von Willebrand factor (Dako, A/S) was used as an endothelial cell marker. Inflammatory markers for human macrophage cells were identified by CD68 staining (CD68/HRP, Dako, A/S). PCNA, a DNA polymerase, was used as a marker for cellular proliferation (Dako). Osteopontin and osteocalcin, glycosylated phosphoproteins important in skeletal bone mineralization, were detected with antibodies obtained from the University of Iowa Hybridoma Bank, anti-osteopontin, and anti-osteocalcin (Abcam).
After fixation, slides were blocked with 3.0% (vol/vol) H 2 O 2 in methanol for 30 minutes, washed with PBS (wt/wt) for 30 minutes, and incubated in primary antibodies for 16 hours at 4°C. Anti-VEGF required a pretreatment antigen enhancing step of heating slides in 95°C 0.1 mol/L citrate buffer, pH 6.0, for 10 minutes before incubation with the anti-VEGF primary antibody. After primary antibody incubations, slides were incubated with biotinylated secondary antibodies (Dako, A/S) for 60 minutes and streptavidin/HRP complex (Dako, A/S) for 60 minutes at room temperature. Slides treated with primary antibody anti-CD68/HRP complex did not require secondary antibodies and were directly developed. To develop color, slides were incubated in 3-amino-9-ethylcarbazole (Sigma Diagnostics, Inc) as a chromogen with 1% (vol/vol) H 2 O 2 for 15 minutes, followed by counterstaining with hematoxylin acid solution (Sigma Diagnostics, Inc) for 10 minutes and washing with H 2 0 for 3 minutes. To provide a degree of quantification to our analysis, PCNA expression was determined with digital image analysis. 4 The samples were scored semiquantitatively for the expression of the immunostains present within the valve tissue and are listed in the Table. Results are also shown qualitatively in the photomicrographs.
Microcomputed Tomography
After fixing in formalin, the valves were examined with a Scanco microcomputed tomography (MicroCT) system (MicroCT-40) operated at 45 kV. Sampling was with Ϸ8-m voxels (volume elements), maximum sensitivity (1000 projections, 2048 samples), and 0.3 second per projection integration 4 (nϭ6 valves total were tested).
Statistical Analysis
Comparison was made among the 3 groups using ANOVA. Scheffé's method of adjustment was performed for multiple pairwise comparisons. All statistical tests were 2 tailed, and values of PϽ0.05 was considered significant.
Results
Immunohistochemistry of the Human Rheumatic Valves for Neoangiogenesis Markers
Hematoxylin and Eosin and Masson Trichrome Stains
Special stains for hematoxylin and eosin and Masson trichrome stains are shown in Figure 1 -A1 and 1-A2. Both the hematoxylin and eosin and the Masson trichrome demonstrate a marked inflammatory cellular infiltrate within the rheumatic valve lesions. In Figure 1 -A2, the Masson trichrome purple staining indicated an increase in collagen synthesis in areas of calcification and mineralization. Furthermore, there were multiple areas of new vessels forming (see arrows) within the valve lesions. Figure 1 -B1 demonstrates the low-power magnification of the ␣-actin staining smooth muscle cells within the areas of neoangiogenesis in the rheumatic valves. Figure 2 -A1 shows that PCNA-positive brown-staining cells were detected in the proliferating myofibroblasts. The total density of PCNA-positive cells was 37.64Ϯ7.3 cells/mm 2 in 
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the rheumatic valves and 1.26Ϯ0.32 cells/mm 2 in control valves (PϽ0.001), as shown in the Table. Osteoblast Bone Markers Figure 2 -A2 shows the immunohistochemistry for osteopontin, a bone matrix protein important in osteoblast mineralization. Figure 2 -A2 demonstrates that osteopontin localizes to the neointima of new vessel formation (the arrow) and proliferating myofibroblasts within the rheumatic valves. Osteocalcin is an osteoblast-specific marker. 6 The arrow in Figure 2 -C2 indicates that osteocalcin is localized to the myofibroblast staining cells. The Table indicates the quantification of the bone matrix markers present in the rheumatic valves compared with the controls.
MicroCT
A 3D analysis of the calcified rheumatic valve by MicroCT reveals the depth and extent of calcification within the valve. Figure 3 -A1 demonstrates the ␣-actin-staining myofibroblast cells localized to the atrial surface of the mitral valves (arrow points to the cells). There was no evidence of new vessels forming within the mitral valves. (magnification ϫ40). C1, von Willebrand factor immunostain (magnification ϫ10). C2, von Willebrand factor immunostain. Arrow points to endothelial layer staining positive for von Willebrand factor (magnification ϫ10). D1, CD68 immunostain for human macrophages (magnification ϫ10). D2, CD68 Immunostain for human macrophages. Arrow points to inflammatory staining cells (magnification ϫ40). E1, VEGF immunostain (magnification ϫ10). E2, VEGF immunostain. Arrow points to areas of VEGF stain in areas of inflammation (magnification ϫ40).
Immunohistochemistry of the Human Mitral Degenerative Valves for Neoangiogenesis Markers
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As Figure 4 -A1 shows, PCNA-positive cells were detected along the surface of the degenerative mitral valves, indicating a mild increase in cellular proliferation. Figure 4 -B1 demonstrates the immunohistochemistry for osteopontin, which is localized along the atrial surface of the mitral valve leaflet. Figure 4-C1 , showing the osteocalcin stains, also demonstrates a mild amount of osteocalcin along the surface of atrial surface. Osteocalcin is an osteoblastspecific marker. 7 The arrow in Figure 4 -D1 indicates that the protein is localized to the myofibroblast staining cells. The Table demonstrates the quantification of the new vessels and the level of PCNA expression in the degenerative mitral valves compared with the rheumatic valves and control tissue.
Osteoblast Bone Markers
Discussion
Calcification of human valves is the most common manifestation of diseased rheumatic heart valves. Until recently, the cellular mechanisms of the calcification process have been thought to be due to a passive accumulation of calcium along the surface of the valve leaflet. We hypothesized that the mechanism for valvular calcification is similar to skeletal bone formation and that calcification occurs in areas of neoangiogenesis, which is stimulated by an active inflammatory process and the release of VEGF. VEGF is well known to play a key role in angiogenesis in pathological inflammatory diseases. 8, 9 Deckers et al 10 have suggested that VEGF regulates bone remodeling by attracting endothelial cells and by stimulating osteoblast differentiation. Our findings indicate that VEGF is localized to cells in inflammatory regions of the valve fibrosa, specifically the macrophages and myofibroblasts. Our group has recently demonstrated that an osteoblast phenotype is associated with nonrheumatic, degenerative calcific aortic stenosis. 4 The current data, including the production of osteopontin and osteocalcin proteins (both osteoblast cell products) and proliferating myofibroblast cells synthesizing bone matrix proteins, indicate that a similar osteoblast-like process that occurs in degenerative calcific aortic stenosis develops in the calcification process in rheumatic valves. 4, 7 The cellular differences between the rheumatic and degenerative lesions are the intense inflammatory infiltrate and the demonstration of VEGF in areas of neoangiogenesis found in the rheumatic valves compared with the degenerative aortic stenosis 4, 5, 11, 12 and in the degenerative mitral valves analyzed in the present study.
Although calcification in rheumatic valves has been described in the literature for Ͼ200 years, 13 the cellular mechanisms responsible for the calcification have not been previously described. These new observations support the hypothesis that mineralization of rheumatic cardiac valve tissue is similar to skeletal bone formation that is associated with neoangiogenesis and show that studying this disease process will provide important information on the treatment of valvular heart disease. Figure 3 . Identification of neoangiogenesis markers in human degenerative mitral valves. A1, ␣-Actin immunostain. Arrow points to actin staining myofibroblast (magnification ϫ40). B1, von Willebrand factor immunostain. Arrow points to endothelial layer along atrial surface of mitral valve (magnification ϫ40). C1, CD68 immunostain (magnification ϫ40). D1, VEGF immunostain. Arrow points to endothelial layer along atrial surface of mitral valve (magnification ϫ40).
Figure 4.
Identification of bone matrix markers in the human degenerative mitral valves. A1, PCNA immunostain. Arrow points to brown staining nuclei (magnification ϫ40). B1, Osteopontin immunostain. Arrow points to myofibroblast cells expressing osteopontin (magnification ϫ40). C1, Osteocalcin immunostain. Arrow points to myofibroblast cells expressing osteocalcin (magnification ϫ40). D1, Alizarin red stain (magnification ϫ40).
